- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06561360
Um estudo de Vemurafenibe e Obinutuzumabe em comparação com Cladribina e Rituximabe em pessoas com leucemia de células pilosas (HCL)
Um estudo randomizado, multicêntrico, de fase II de Vemurafenibe mais obinutuzumabe vs. Cladribina mais rituximabe em pacientes com leucemia de células pilosas (HCL) não tratada anteriormente
The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer or milder side effects. Researchers think vemurafenib and obinutuzumab (non-chemotherapy drugs) may cause fewer side effects compared with the usual approach of chemotherapy drugs. They will also compare the two approaches to see which approach is more effective at eliminating cancer cells.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Jae Park, MD
- Número de telefone: 646-608-3743
- E-mail: parkj6@mskcc.org
Estude backup de contato
- Nome: Mark Geyer, MD
- Número de telefone: 646-608-3745
Locais de estudo
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Ainda não está recrutando
- Dana Farber Cancer Institute
-
Contato:
- Eric Winer, MD
- Número de telefone: (617) 632-6876
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Ainda não está recrutando
- Mayo Clinic Cancer Center
-
Contato:
- Sameer Parikh, M.B.B.S.
- Número de telefone: 507-218-0772
-
-
New Jersey
-
Basking Ridge, New Jersey, Estados Unidos, 07920
- Recrutamento
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)
-
Contato:
- Jae Park, MD
- Número de telefone: 646-608-3743
-
Middletown, New Jersey, Estados Unidos, 07748
- Recrutamento
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
-
Contato:
- Jae Park, MD
- Número de telefone: 646-608-3743
-
Montvale, New Jersey, Estados Unidos, 07645
- Recrutamento
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)
-
Contato:
- Jae Park, MD
- Número de telefone: 646-608-3743
-
-
New York
-
Commack, New York, Estados Unidos, 11725
- Recrutamento
- Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities)
-
Contato:
- Jae Park, MD
- Número de telefone: 646-608-3743
-
Harrison, New York, Estados Unidos, 10604
- Recrutamento
- Memorial Sloan Kettering Westchester (All Protocol Activities)
-
Contato:
- Jae Park, MD
- Número de telefone: 646-608-3743
-
New York, New York, Estados Unidos, 10065
- Recrutamento
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)
-
Contato:
- Jae Park, MD
- Número de telefone: 646-608-3743
-
Uniondale, New York, Estados Unidos, 11553
- Recrutamento
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)
-
Contato:
- Jae Park, MD
- Número de telefone: 646-608-3743
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- Recrutamento
- Ohio State University
-
Contato:
- Seema Bhat, MD
- Número de telefone: 614-293-3196
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Patients must be ≥ 18 years of age
-
Histologically confirmed classical HCL by the enrolling institution
-
Presence of BRAF V600E mutation as confirmed by PCR, NGS or immunohistochemistry. If patient is known to have negative BRAF mutation, repeat testing is advisable as well as discussion with the main study principal investigator.
-
Has not received any prior therapy for the disease
-
Patients who meet the standard treatment initiation criteria, as defined by ANC ≤1.0, Hgb ≤ 10.0 or PLT ≤100K
-
ECOG performance status of 0 - 2
-
Acceptable pre-study organ function during screening as defined as:
- Total bilirubin ≤ 1.5 times the upper limit of normal (ULN), except in patients with known Gilbert's syndrome who may be enrolled if direct bilirubin ≤ 3 x ULN);
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x ULN; and
- Serum creatinine ≤ 1.5x ULN
-
Electrocardiogram (ECG) without evidence of clinically significant ventricular arrhythmias or ischemia as determined by the investigator and a rate-corrected QT interval (QTc, Bazett's formula) of < 480 msec
-
For women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for 6 months after discontinuation of vemurafenib and cladribine, and 18 months after discontinuation of rituximab and obinutuzumab
-
For men with female partners of childbearing potential, agreement to use a latex condom and to advise their female partner to use an additional method of contraception during the study and for 6 months after discontinuation of vemurafenib
-
Negative serum pregnancy test within 7 days of commencement of treatment in women of childbearing potential
Exclusion Criteria:
-
Have had previous treatment for HCL, including purine analogs, vemurafenib, rituximab, obinutuzumab, and other investigational agents. Previous treatment with transfusions and other supportive care such as G-CSF and erythropoietin are allowed.
-
Known hypersensitivity to any of the study drugs.
-
Patients with known long QT syndrome or uncorrectable electrolyte abnormalities
-
Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.
-
Presence of positive test results for hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg) or hepatitis C (HCV) antibody
° Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody [HBcAb] and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing and take HBV viral prophylaxis such as entecavir.
-
Known infection with HIV or human T-cell leukemia virus 1 (HTLV-1)
-
Active uncontrolled infection, e.g. persistent bacteremia, supplemental oxygen or pressor supports, etc.
-
Live vaccination within 28 days of randomization
-
Patients with concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of the skin, in situ cervical cancer, adequately treated stage I/II cancer from which the patient is current in complete remission, or any other cancer from which the patient has been disease free for five years
-
Malabsorption syndrome or other condition that precludes enteral route of administration
-
Patients with HCL variant (as defined by absence of expression of CD25)
-
Pregnant or lactating, or intending to become pregnant during the study
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Vemurafenib plus Obinutuzumab
Patients assigned to the study arm will receive vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. Obinutuzumab infusions will be administered on days 1, 8 and 15 during the cycle 2 and every 4 weeks during the cycle 3 and 4 of treatment. |
Vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. |
|
Comparador Ativo: Standard treatment of Cladribine plus Rituximab
Patients assigned to the SOC arm will receive cladribine IV on days 1-5 concurrently with rituximab IV per week for 8 times, i.e., weekly x8 from day 1. |
Cladribine IV on days 1-5 concurrently with rituximab. Rituximab on days 1-5 concurrently with rituximab. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
incidences of ≥ grade 3 treatment-related toxicities
Prazo: within 6 months of treatment
|
per CTCAE v5.0 within first 6 months from the start of the treatment to account delayed toxicities of the treatments |
within 6 months of treatment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
complete remission
Prazo: 2 years
|
Response will be determined by the Consensus Resolution response criteria. Complete response (CR)
|
2 years
|
|
partial response
Prazo: 2 years
|
Partial response (PR) °A normalization of cytopenias °≥50% reduction in organomegaly and bone marrow hairy cells. |
2 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jae Park, MD, Memorial Sloan Kettering Cancer Center
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Neoplasias
- Doenças do sistema imunológico
- Neoplasias por Tipo Histológico
- Doenças Hematológicas
- Doenças Linfáticas
- Distúrbios Linfoproliferativos
- Distúrbios imunoproliferativos
- Leucemia
- Doenças hemic e linfáticas
- Leucemia de Células Cabeludas
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Compostos de enxofre
- Produtos químicos orgânicos
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Ácidos nucleicos, nucleotídeos e nucleosídeos
- Amidas
- Indoles
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Purinas
- Nucleosídeos
- Ribonucleosídeos
- Anticorpos, monoclonais, derivados de murinos
- Desoxirribonucleosídeos
- Sulfonamidas
- Sulfonas
- 2-cloroadenosina
- Adenosina
- Nucleosídeos de purina
- Desoxiadenosinas
- Rituximabe
- Vemurafenibe
- Cladribina
- Obinutuzumab
Outros números de identificação do estudo
- 24-160
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .